| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of dysbetalipoproteinemia: diagnostic and therapeutic strategies
|
Dhar, Kalyani
|
|
|
19 |
3S |
p. e8-e9
|
artikel
|
| 2 |
A case report of hyperchylomicronemia and recurrent pancreatitis in a patient with the pArg333His variant of the lipoprotein lipase gene
|
Gant, Lonnell
|
|
|
19 |
3S |
p. e31-e32
|
artikel
|
| 3 |
Accelerated atherosclerosis post liver transplant associated to MetALD: atherogenic dyslipidemia post-transplant as a forgotten risk marker.
|
Vergara, Carlos
|
|
|
19 |
3S |
p. e32-e33
|
artikel
|
| 4 |
Accelerating evidence generation to implementation in cardiometabolic health: Establishment of the LATTICE Consortium
|
Jones, Laney
|
|
|
19 |
3S |
p. e5-e6
|
artikel
|
| 5 |
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study
|
Aliu, Oiza
|
|
|
19 |
3S |
p. e4-e5
|
artikel
|
| 6 |
Adherence to recent evidence-based guidelines for statin therapy in primary prevention for type 2 diabetes patients: A quality improvement initiative
|
Patel, Prit
|
|
|
19 |
3S |
p. e56-e57
|
artikel
|
| 7 |
Adult onset very long chain acyl-CoA dehydrogenase deficiency: A case report
|
Sahinoz, Melis
|
|
|
19 |
3S |
p. e71
|
artikel
|
| 8 |
A novel gamified ambulatory curriculum to educate internal medicine residents on lifestyle medicine and counseling
|
Ammari, Nadim
|
|
|
19 |
3S |
p. e15
|
artikel
|
| 9 |
A plasma glycan score for cardiovascular risk prediction: Secondary analysis of the JUPITER and TNT studies
|
Ammar, Mohammed
|
|
|
19 |
3S |
p. e26-e27
|
artikel
|
| 10 |
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels
|
Gao, Xiang
|
|
|
19 |
3S |
p. e108
|
artikel
|
| 11 |
Assessing LDL-C goal attainment in secondary prevention of atherosclerotic cardiovascular disease: Insights from the LAI-LCARE survey in India
|
Puri, Raman
|
|
|
19 |
3S |
p. e64-e65
|
artikel
|
| 12 |
Assessing the burden of lipodystrophy: Insights from a patient-driven survey
|
Halperin, Sharon
|
|
|
19 |
3S |
p. e120
|
artikel
|
| 13 |
Assessment of coronary plaque and plaque characteristics on coronary CT angiography among South Asian individuals in the DILWALE registry
|
Agarwala, Anandita
|
|
|
19 |
3S |
p. e82
|
artikel
|
| 14 |
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece
|
Paparodis, Rodis
|
|
|
19 |
3S |
p. e83
|
artikel
|
| 15 |
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data
|
Kodjoe, Elsie
|
|
|
19 |
3S |
p. e59
|
artikel
|
| 16 |
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates
|
Leon, Dairene
|
|
|
19 |
3S |
p. e96-e97
|
artikel
|
| 17 |
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis
|
Yousafzai, Osman
|
|
|
19 |
3S |
p. e27
|
artikel
|
| 18 |
Association of serum lipoprotein(a) and progression of structural heart disease: Insights from CARDIA study
|
Butte, Zara
|
|
|
19 |
3S |
p. e22
|
artikel
|
| 19 |
Associations of serum omega-3 polyunsaturated fatty acids with apolipoprotein B and atherogenic lipoprotein lipids
|
Kirkpatrick, Carol
|
|
|
19 |
3S |
p. e62
|
artikel
|
| 20 |
Associations of serum omega-6 polyunsaturated fatty acids with apolipoprotein B and atherogenic lipoprotein lipids
|
Maki, Kevin
|
|
|
19 |
3S |
p. e62-e63
|
artikel
|
| 21 |
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD
|
Karamardian, Michael
|
|
|
19 |
3S |
p. e36-e37
|
artikel
|
| 22 |
*A unique case of xanthoma tendinosum
|
Vartak, Natasha
|
|
|
19 |
3S |
p. e35-e36
|
artikel
|
| 23 |
Behavioral risk factors and biomarkers of cardiovascular health in transgender and nonbinary individuals
|
Berruti, Alaina
|
|
|
19 |
3S |
p. e50-e51
|
artikel
|
| 24 |
Beyond homozygous familial hypercholesterolemia – emerging therapy for severe familial hypercholesterolemia phenotypes
|
Haynes, Tiffany
|
|
|
19 |
3S |
p. e77
|
artikel
|
| 25 |
Bridging the gap: enhancing lipoprotein(a) testing and education in federally qualified health centers
|
Skinner, Jeremy
|
|
|
19 |
3S |
p. e21
|
artikel
|
| 26 |
BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in human subjects
|
Redzepagic, Emir
|
|
|
19 |
3S |
p. e105
|
artikel
|
| 27 |
Cardiac arrest risk and outcomes in SLE patients with protein-calorie malnutrition
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e127-e128
|
artikel
|
| 28 |
Cardiometabolic disease associated markers begin to increase at an A1C > 5%
|
Penn, Marc
|
|
|
19 |
3S |
p. e123-e124
|
artikel
|
| 29 |
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study
|
Ajenaghughrure, Godbless
|
|
|
19 |
3S |
p. e87
|
artikel
|
| 30 |
Care of youth with lipid disorders: A brief provider survey
|
Rashad, Maya
|
|
|
19 |
3S |
p. e17-e19
|
artikel
|
| 31 |
Cholesterol-responsive NFE2L1-INSIG1 interaction is critical for VLDL biogenesis and hepatic health
|
Deng, Shijun
|
|
|
19 |
3S |
p. e121-e122
|
artikel
|
| 32 |
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM
|
Ferdinand, Keith
|
|
|
19 |
3S |
p. e11
|
artikel
|
| 33 |
Clinical outcomes in patients admitted with diabetic ketoacidosis & hypernatremia, according to a nation-wide dataset
|
Hammas, Mian
|
|
|
19 |
3S |
p. e63
|
artikel
|
| 34 |
Clinical outcomes in patients hospitalized with diabetic ketoacidosis and acute pancreatitis: A nationwide analysis
|
Hammas, Mian
|
|
|
19 |
3S |
p. e65
|
artikel
|
| 35 |
Clinical outcomes of COVID-19 among patients with pure hypertriglyceridemia: A large-scale retrospective cohort study
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e86
|
artikel
|
| 36 |
Clinical Pharmacology of Olezarsen, a Novel ApoC-III Targeted Antisense Inhibitor, for Reducing Triglycerides in Patients with Familial Chylomicronemia Syndrome
|
Yu, Rosie
|
|
|
19 |
3S |
p. e108-e109
|
artikel
|
| 37 |
Closing the unmet gap: High-intensity lipid-lowering therapy and 28-day LDL-C goal achievement in patients with ACS
|
Pradhan, Akshyaya
|
|
|
19 |
3S |
p. e98
|
artikel
|
| 38 |
Community pharmacist impact of addressing statin use in patients with diabetes
|
Nee, Cindy
|
|
|
19 |
3S |
p. e124
|
artikel
|
| 39 |
Comparative Cardiovascular Outcomes of Triple Lipid-Lowering Therapy versus Double Therapy in Patients with Atherosclerotic Cardiovascular Disease
|
Ajenaghughrure, Godbless
|
|
|
19 |
3S |
p. e17
|
artikel
|
| 40 |
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease
|
Ajenaghughrure, Godbless
|
|
|
19 |
3S |
p. e20
|
artikel
|
| 41 |
Comparison of diagnostic genetic testing and clinical scoring results for familial chylomicronemia syndrome (FCS) in the 66-patient Balance study
|
Brown, Alan
|
|
|
19 |
3S |
p. e73
|
artikel
|
| 42 |
Comparison of systemic outcomes in metabolic dysfunction-associated steatotic liver disease patients with dyslipidemia and chronic kidney disease: A prospective case-control study
|
Mateo, Fernando
|
|
|
19 |
3S |
p. e103-e104
|
artikel
|
| 43 |
Comparison of systemic outcomes in metabolic dysfunction-associated steatotic liver disease patients with dyslipidemia and heart failure: A prospective case-control study
|
Mateo, Fernando
|
|
|
19 |
3S |
p. e102-e103
|
artikel
|
| 44 |
Comparison of the performance of three diagnosis scoring systems in patients with persistent chylomicronemia of different causes
|
Brisson, Diane
|
|
|
19 |
3S |
p. e25-e26
|
artikel
|
| 45 |
Comparison of the pooled cohort and the PREVENT cardiovascular disease risk equations in the veteran's health administration
|
King, Sara
|
|
|
19 |
3S |
p. e44-e45
|
artikel
|
| 46 |
Coronary artery disease in a zero calcium score patient: questioning the reliability of CAC in high-risk individuals
|
Mousa, Marlin
|
|
|
19 |
3S |
p. e35
|
artikel
|
| 47 |
Dedicated training in obesity management: A pathway to better physician practice
|
Wallach, Yisrael
|
|
|
19 |
3S |
p. e88
|
artikel
|
| 48 |
Detection of a heterozygous mutation in ABCG8 in a patient with extensive premature coronary artery disease
|
Rajai, Nazanin
|
|
|
19 |
3S |
p. e81
|
artikel
|
| 49 |
Development of a dual functional RNAi therapeutic, ARO-DIMER-PA, for mixed hyperlipidemia
|
Van Dyke, Jonathan
|
|
|
19 |
3S |
p. e111-e112
|
artikel
|
| 50 |
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories
|
Truitte, Ryan
|
|
|
19 |
3S |
p. e83-e84
|
artikel
|
| 51 |
Does baseline risk of atherosclerotic cardiovascular disease associate with the treatment effect of primary prevention statins on all-cause mortality?
|
Yazgi, Habib
|
|
|
19 |
3S |
p. e95
|
artikel
|
| 52 |
Double heterozygosity for variants in ABCG8 and ABCG5 and potential association with sitosterolemia
|
Brown, Sidney
|
|
|
19 |
3S |
p. e69
|
artikel
|
| 53 |
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e85-e86
|
artikel
|
| 54 |
Early Triple Lipid-Lowering Therapy in Acute Coronary Syndrome: Results from the multicentric LAI-REACT Study
|
Puri, Raman
|
|
|
19 |
3S |
p. e12-e13
|
artikel
|
| 55 |
Educating providers about coronary artery calcium scoring testing in atherosclerotic cardiovascular disease risk stratification and racial disparities
|
Kaur, Manpreet
|
|
|
19 |
3S |
p. e48
|
artikel
|
| 56 |
Effectiveness of bempedoic acid and bempedoic acid plus ezetimibe on LDL-C in a real-world cohort
|
Sarnes, Evelyn
|
|
|
19 |
3S |
p. e94-e95
|
artikel
|
| 57 |
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor
|
Zhang, Yongkang
|
|
|
19 |
3S |
p. e29
|
artikel
|
| 58 |
Effect of ANGPTL3 Inhibition on Remnant Cholesterol Subtypes
|
Rodriguez, Carla
|
|
|
19 |
3S |
p. e115-e116
|
artikel
|
| 59 |
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e61
|
artikel
|
| 60 |
Effect of Obicetrapib on New Onset Diabetes In Patients with Elevated LDL-C Receiving Maximally Tolerated Statin Therapy: Pooled Analyses of the Broadway and Brooklyn Trials
|
Ray, Kausik K.
|
|
|
19 |
3S |
p. e116-e117
|
artikel
|
| 61 |
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia
|
Ballantyne, Christie
|
|
|
19 |
3S |
p. e85
|
artikel
|
| 62 |
Effects of PCSK9 inhibitors on morphology of coronary atheroma in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials
|
Thakurathi, Priyesh
|
|
|
19 |
3S |
p. e107-e108
|
artikel
|
| 63 |
† Elevated HDL in familial hyper-alpha-lipoproteinemia: Atheroprotective or atherogenic?
|
Manji, Zahra
|
|
|
19 |
3S |
p. e33
|
artikel
|
| 64 |
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy
|
Mahajan, Kunal
|
|
|
19 |
3S |
p. e13
|
artikel
|
| 65 |
Epidemiology and longitudinal course of chylomicronemia: Insights from NHANES and a large health care system
|
Saadatagah, Seyedmohammad
|
|
|
19 |
3S |
p. e6
|
artikel
|
| 66 |
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population
|
Nuvvula, Sri
|
|
|
19 |
3S |
p. e1-e2
|
artikel
|
| 67 |
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration
|
King, Sara
|
|
|
19 |
3S |
p. e20-e21
|
artikel
|
| 68 |
Evaluation of PCSK9 inhibitors in patients with hyperlipidemia
|
Khin, May Oo
|
|
|
19 |
3S |
p. e97-e98
|
artikel
|
| 69 |
Exome sequencing identifies genetic-positive familial hypercholesterolemia within a multi-site healthcare system
|
Schroeder, Mariah
|
|
|
19 |
3S |
p. e70
|
artikel
|
| 70 |
Extreme lipoprotein(a) levels and the risk of acute myocardial infarction by standard modifiable cardiovascular risk factors among US adults
|
Marchlewicz, Elizabeth
|
|
|
19 |
3S |
p. e3-e4
|
artikel
|
| 71 |
Ezetimibe may help inform diagnosis in severe hypercholesterolemia: Sitosterolemia in a 2-year-old female
|
Newman, Taylor
|
|
|
19 |
3S |
p. e123
|
artikel
|
| 72 |
Familial LCAT deficiency: A rare cause of severe proteinuria
|
Manji, Zahra
|
|
|
19 |
3S |
p. e75-e76
|
artikel
|
| 73 |
Genetically confirmed atypical cerebrotendinous xanthomatosis with large xanthomas and normal plasma cholestanol in an octogenarian
|
Duell, P. Barton
|
|
|
19 |
3S |
p. e39-e41
|
artikel
|
| 74 |
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study
|
Watts, Carolyn
|
|
|
19 |
3S |
p. e71
|
artikel
|
| 75 |
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia
|
Kessler, Asia Sikora
|
|
|
19 |
3S |
p. e118-e119
|
artikel
|
| 76 |
Healthcare resource utilization patterns in SLE with protein-calorie malnutrition: A national analysis
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e128
|
artikel
|
| 77 |
Healthcare system level testing for lipoprotein(a) amongst ischemic and cryptogenic stroke patient population
|
Levene, Jacqueline
|
|
|
19 |
3S |
p. e9-e11
|
artikel
|
| 78 |
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice
|
Kessler, Asia Sikora
|
|
|
19 |
3S |
p. e119-e120
|
artikel
|
| 79 |
How do diabetes medications affect metabolic dysfunction associated steatotic liver disease and associated lipid parameters in elderly patients
|
Sen, Sabyasachi
|
|
|
19 |
3S |
p. e99
|
artikel
|
| 80 |
Hypercholesterolemia management in a patient with mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes
|
Anderson, Gretchen
|
|
|
19 |
3S |
p. e41-e42
|
artikel
|
| 81 |
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery
|
Golwala, Sohil
|
|
|
19 |
3S |
p. e43-e44
|
artikel
|
| 82 |
† Impact of adjunctive lipid-modifying therapy in the CLEAR Outcomes Ttial
|
Menon, Venu
|
|
|
19 |
3S |
p. e93
|
artikel
|
| 83 |
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers
|
Pradhan, Akshyaya
|
|
|
19 |
3S |
p. e65-e66
|
artikel
|
| 84 |
Impact of grant-funded carotid intima-media thickness ultrasound on cardiovascular risk assessment and management in an underserved population
|
Sangoi, Matthew
|
|
|
19 |
3S |
p. e49
|
artikel
|
| 85 |
Impact of lipid-lowering medications on cardiovascular outcomes and lipid profiles in NAFLD/NASH patients: A 5-year retrospective cohort study
|
Yousafzai, Osman
|
|
|
19 |
3S |
p. e104-e105
|
artikel
|
| 86 |
Impact of PCSK9 inhibitors and nucleic acid-based therapies on lipoprotein(a) concentrations in non-familial hypercholesterolemia patients
|
Nudy, Matthew
|
|
|
19 |
3S |
p. e93-e94
|
artikel
|
| 87 |
Impact of PCSK9 loss-of-function mutation on metabolic and liver health: A case of metabolic dysfunction-associated steatohepatitis and insulin resistance associated with a unique PCSK9 loss-of-function mutation
|
Golwala, Sohil
|
|
|
19 |
3S |
p. e80-e81
|
artikel
|
| 88 |
Impact of PCSK9 monoclonal antibody inhibitors on Lp(a) reduction in African Americans with elevated Lp(a)
|
Hasham, Salman
|
|
|
19 |
3S |
p. e54
|
artikel
|
| 89 |
Impact of polygenic risk score on the use of lipid-lowering therapy in primary prevention for coronary artery disease
|
Sangoi, Matthew
|
|
|
19 |
3S |
p. e25
|
artikel
|
| 90 |
Impact of protein-calorie malnutrition on outcomes in patients admitted with acute pancreatitis: Insights from the National Inpatient Sample
|
Rahima, M Kenan
|
|
|
19 |
3S |
p. e67-e68
|
artikel
|
| 91 |
Impact of the cholesteryl ester transfer protein inhibitor, Obicetrapib, on lipoprotein(a) levels: Pooled data from phase 3 clinical trials
|
Nicholls, Stephen J
|
|
|
19 |
3S |
p. e99-e100
|
artikel
|
| 92 |
Impact of value-based comprehensive medication management on statin prescribing in patients with type 2 diabetes mellitus
|
Kakwani, Anjali
|
|
|
19 |
3S |
p. e57
|
artikel
|
| 93 |
Improving adherence to universal lipid screening in pediatric patients at a tertiary healthcare system in new jersey through a quality improvement initiative
|
Haynes, Tiffany
|
|
|
19 |
3S |
p. e14-e15
|
artikel
|
| 94 |
Improving adherence with lipid-lowering agents
|
Yung, Lau Yan
|
|
|
19 |
3S |
p. e55-e56
|
artikel
|
| 95 |
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities
|
Alur-Gupta, Snigdha
|
|
|
19 |
3S |
p. e58-e59
|
artikel
|
| 96 |
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins
|
Davidson, Michael H
|
|
|
19 |
3S |
p. e100
|
artikel
|
| 97 |
Integrating lipoprotein(a) into a cardiometabolic health curriculum for internal medicine residents: Gamified vs. traditional lecture for knowledge retention
|
Cyr, Andrew
|
|
|
19 |
3S |
p. e26
|
artikel
|
| 98 |
Intubation rates and risk factors in SLE patients with protein-calorie malnutrition
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e55
|
artikel
|
| 99 |
Ketogenic diets exacerbating dyslipidemia: The role of lipid testing, genetic testing and advanced cardiac imaging
|
Alam, Loba
|
|
|
19 |
3S |
p. e28
|
artikel
|
| 100 |
LDL-C management with inclisiran plus usual care vs usual care alone in participants with recent acute coronary syndrome: VICTORION-INCEPTION
|
Knowlton, Kirk
|
|
|
19 |
3S |
p. e109-e110
|
artikel
|
| 101 |
Lipid-lowering intensification post-ACS in very high-risk patients on high-intensity statins: Insights from a mayo clinic registry
|
Wang, Winston
|
|
|
19 |
3S |
p. e13-e14
|
artikel
|
| 102 |
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.
|
Paparodis, Rodis
|
|
|
19 |
3S |
p. e92-e93
|
artikel
|
| 103 |
Lipoprotein(a) Cholesterol, Randomized Omega-3 Fatty Acid Supplementation, and Cardiovascular Events: Extended Follow-up in the VITamin D and OmegA 3 TriaL
|
Farukhi, Zareen
|
|
|
19 |
3S |
p. e66
|
artikel
|
| 104 |
Lipoprotein(a) concentrations across a global cross-sectional registry
|
Said, Samer Al
|
|
|
19 |
3S |
p. e124-e125
|
artikel
|
| 105 |
Lipoprotein apheresis to address residual risk in recurrent atherosclerotic events
|
Mangla, Mahima
|
|
|
19 |
3S |
p. e37-e38
|
artikel
|
| 106 |
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients
|
Kao, Andrew
|
|
|
19 |
3S |
p. e24
|
artikel
|
| 107 |
Local contractile activity of the soleus causes potent lipoprotein lipase-dependent enhancement of low-density lipoprotein triglyceride metabolism
|
LeBlanc, Daniel
|
|
|
19 |
3S |
p. e88-e89
|
artikel
|
| 108 |
† Lomitapide in pediatric patients with HoFH – analysis of long-term (104-week) safety and efficacy from the APH-19 study
|
Masana, Luis
|
|
|
19 |
3S |
p. e125-e126
|
artikel
|
| 109 |
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments
|
Chebli, Jasmine
|
|
|
19 |
3S |
p. e69
|
artikel
|
| 110 |
Loss of lipid-lowering effect of evolocumab over time: A case report
|
Soon-Shiong, Raquel
|
|
|
19 |
3S |
p. e37
|
artikel
|
| 111 |
† Low-dose obicetrapib significantly increases concentrations of lipophilic antioxidants, ApoE, and S1P in HDL subfractions
|
Niesor, Eric
|
|
|
19 |
3S |
p. e113-e114
|
artikel
|
| 112 |
Management of complex lipid disorders in a community lipid clinic setting
|
Miyamoto, Michael
|
|
|
19 |
3S |
p. e8
|
artikel
|
| 113 |
Maximal triglyceride and DNA methylation levels are independently associated with prevalence of ASCVD in multifactorial chylomicronemia syndrome
|
Guay, Simon-Pierre
|
|
|
19 |
3S |
p. e74
|
artikel
|
| 114 |
Maximizing LDL management: The power of EHR alerts and patient follow-up
|
Abualenain, Mohammed
|
|
|
19 |
3S |
p. e16-e17
|
artikel
|
| 115 |
Medical nutrition therapy helps lower triglycerides in patients with chylomicronemia and type 2 diabetes: A case series
|
Biggins, Anna
|
|
|
19 |
3S |
p. e89
|
artikel
|
| 116 |
Moving triglycerides off the “back burner”: Developing a tailored approach to managing ASCVD risk in post-ACS patients
|
Salvati, Zachary
|
|
|
19 |
3S |
p. e45-e46
|
artikel
|
| 117 |
Non-atrial fibrillation arrhythmias among hospitalized non-diabetic adults with metabolic syndrome and insulin resistance in the USA
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e102
|
artikel
|
| 118 |
No observable disparities in the use of plasmapheresis in severe triglyceride-related acute pancreatitis: Insights from the National Inpatient Sample
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e52-e53
|
artikel
|
| 119 |
† Obicetrapib alone and in combination with ezetimibe increases reverse cholesterol transport and does not affect VLDL production
|
Inia, José
|
|
|
19 |
3S |
p. e112
|
artikel
|
| 120 |
Obicetrapib lowers LDL-cholesterol by substantially increasing LDL-ApoB clearance rates in humans
|
Bajaj, Archna
|
|
|
19 |
3S |
p. e120-e121
|
artikel
|
| 121 |
† Obicetrapib reduces atherosclerosis and vascular inflammation, mainly by reducing non-HDL-C, improves lesion stability adding to the beneficial effect of ezetimibe
|
Inia, José A. Inia
|
|
|
19 |
3S |
p. e111
|
artikel
|
| 122 |
† Obicetrapib significantly increases plasma and HDL-levels of lipophilic antioxidants
|
Niesor, Eric
|
|
|
19 |
3S |
p. e112-e113
|
artikel
|
| 123 |
† Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk - A systematic review and meta-analysis
|
Asghar, Muhammad Sohaib
|
|
|
19 |
3S |
p. e89-e90
|
artikel
|
| 124 |
† Omega-3 index improves upon the pooled cohort equation in predicting risk for CVD
|
Harris, William
|
|
|
19 |
3S |
p. e22-e23
|
artikel
|
| 125 |
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy
|
Rajesh, Athul
|
|
|
19 |
3S |
p. e29-e30
|
artikel
|
| 126 |
Outcomes of hyperglycemic emergencies among African Americans compared to Caucasians: A large-scale nationwide analysis
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e52
|
artikel
|
| 127 |
Outcomes of hyperglycemic emergencies among Asian Americans compared to Caucasians: A survey-weighted nationwide assessment of health equity
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e51-e52
|
artikel
|
| 128 |
Outcomes of percutaneous coronary intervention among patients with metabolic dysfunction-associated steatotic liver disease: A nationwide study
|
Ogunniyi, Kayode
|
|
|
19 |
3S |
p. e61-e62
|
artikel
|
| 129 |
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction
|
Karalis, Dean
|
|
|
19 |
3S |
p. e2-e3
|
artikel
|
| 130 |
Phytosterolemia: A case of paradoxical hypercholesterolemia in response to a mediterranean diet
|
Suleman, Saman
|
|
|
19 |
3S |
p. e34-e35
|
artikel
|
| 131 |
Plozasiran decreases the risk of acute pancreatitis and may improve quality of life in familial chylomicronemia syndrome
|
Watts, Gerald
|
|
|
19 |
3S |
p. e76
|
artikel
|
| 132 |
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia
|
Baass, Alexis
|
|
|
19 |
3S |
p. e75
|
artikel
|
| 133 |
Preliminary results of a multifaceted intervention to improve guideline-directed lipid-lowering therapy in patients with recent MI
|
Mackey, Rachel
|
|
|
19 |
3S |
p. e15-e16
|
artikel
|
| 134 |
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma
|
Dasari, Mahati
|
|
|
19 |
3S |
p. e38
|
artikel
|
| 135 |
Prevalence, baseline characteristics, and reclassification of indeterminate genetic results in patients eligible for the Balance trial with olezarsen
|
Dibble, Andrew
|
|
|
19 |
3S |
p. e72
|
artikel
|
| 136 |
Prevalence of blood cholesterol screening, elevated levels, and medication use among adults – United States, 2019-2023
|
Xu, Kerui
|
|
|
19 |
3S |
p. e57-e58
|
artikel
|
| 137 |
Prevalence of obesity and atherosclerotic cardiovascular disease risk factors among South Asians in the DILWALE registry
|
Agarwala, Anandita
|
|
|
19 |
3S |
p. e101
|
artikel
|
| 138 |
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)
|
Radfar, Navid
|
|
|
19 |
3S |
p. e6-e7
|
artikel
|
| 139 |
Protein-calorie malnutrition in SLE: A comprehensive analysis of outcomes and risk factors
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e86-e87
|
artikel
|
| 140 |
Racial disparities in clinical outcomes among systemic lupus erythematosus patients with protein-calorie malnutrition: A national analysis
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e127
|
artikel
|
| 141 |
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation
|
Patel, Prit
|
|
|
19 |
3S |
p. e50
|
artikel
|
| 142 |
Rapid progression of carotid artery stenosis in a postmenopausal patient with untreated familial hypercholesterolemia
|
Mullen, Isabelle
|
|
|
19 |
3S |
p. e77-e78
|
artikel
|
| 143 |
† Real-world safety and effectiveness of lomitapide in homozygous familial hypercholesterolemia over 10 years: Data from LOWER
|
Blom, Dirk
|
|
|
19 |
3S |
p. e95-e96
|
artikel
|
| 144 |
Risk of acute pancreatitis among patients with hypertriglyceridemia (HTG) or severe hypertriglyceridemia (sHTG)
|
Kessler, Asia Sikora
|
|
|
19 |
3S |
p. e67
|
artikel
|
| 145 |
RN026: A lipoprotein(a) targeting siRNA with superior efficacy, extended duration and excellent safety profiles
|
Yang, Xiaoyan
|
|
|
19 |
3S |
p. e115
|
artikel
|
| 146 |
RNA therapeutics for the potential treatment of heterozygous familial hypercholesterolemia
|
Yang, Hsiu-Chiung
|
|
|
19 |
3S |
p. e110-e111
|
artikel
|
| 147 |
Role of cascade genetic testing for the diagnosis and management of familial hypercholesterolemia: A case of compound heterozygous sitosterolemia
|
Qian, Frank
|
|
|
19 |
3S |
p. e30-e31
|
artikel
|
| 148 |
† Safety and efficacy of cholesteryl ester transfer protein inhibition: From genetics to outcome trials
|
Ference, Brian
|
|
|
19 |
3S |
p. e60
|
artikel
|
| 149 |
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia
|
Nicholls, Stephen
|
|
|
19 |
3S |
p. e91
|
artikel
|
| 150 |
† Sebelipase alfa results in sustained improvement of lipid parameters in symptomatic LAL-D: Longitudinal data from the International LAL-D Registry
|
Wilson, Don
|
|
|
19 |
3S |
p. e80
|
artikel
|
| 151 |
Sex differences in cardiovascular outcomes among patients with elevated Lipoprotein(a).
|
Abdelazeem, Basel
|
|
|
19 |
3S |
p. e59-e60
|
artikel
|
| 152 |
SHASTA-5 rationale and design: Randomized, double-blind, placebo-controlled study to evaluate plozasiran efficacy and safety in sHTG at risk for AP
|
Moriarty, Patrick
|
|
|
19 |
3S |
p. e106-e107
|
artikel
|
| 153 |
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report
|
Anum, FNU
|
|
|
19 |
3S |
p. e42-e43
|
artikel
|
| 154 |
Socioeconomic and racial disparities in type 1 diabetes adult patients admitted with diabetic ketoacidosis according to large national data set
|
Rahima, M Kenan
|
|
|
19 |
3S |
p. e53-e54
|
artikel
|
| 155 |
Statin use among uninsured individuals in a charity community clinic
|
Ingle, Tanvi
|
|
|
19 |
3S |
p. e53
|
artikel
|
| 156 |
Suboptimal response to monoclonal antibodies to subtilisin/kexin type 9: A step towards personalizing approach to lipid-modifying therapy
|
Safarova, Maya
|
|
|
19 |
3S |
p. e91-e92
|
artikel
|
| 157 |
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.
|
Farah, Michel
|
|
|
19 |
3S |
p. e96
|
artikel
|
| 158 |
Switching to success: Managing hyperlipidemia by switching between PCSK9 inhibitors
|
Khawaja, Uneza
|
|
|
19 |
3S |
p. e114-e115
|
artikel
|
| 159 |
Temporal trends in mortality among SLE patients with protein-calorie malnutrition
|
Faxas, Sila Mateo
|
|
|
19 |
3S |
p. e126
|
artikel
|
| 160 |
*The association between lipoprotein(a) testing, lipid lowering therapy intensification, and low-density lipoprotein cholesterol goal attainment
|
Furst, Adam
|
|
|
19 |
3S |
p. e45
|
artikel
|
| 161 |
The atherogenic index of plasma (AIP) and remnant-like particle cholesterol (RLP-C) as prognostic biomarkers of post-PCI adverse cardiovascular events
|
Hosseini, Kaveh
|
|
|
19 |
3S |
p. e23-e24
|
artikel
|
| 162 |
The burdens and barriers of optimizing LDL-C management: A survey of physicians in the United States
|
Bash, Lori
|
|
|
19 |
3S |
p. e7
|
artikel
|
| 163 |
The challenges of lipoprotein(a)
|
Danley, Kelsey
|
|
|
19 |
3S |
p. e33-e34
|
artikel
|
| 164 |
The gift that keeps on giving: Post-menopausal elevation in lipoprotein(a)
|
Bhatia, Ranvir
|
|
|
19 |
3S |
p. e39
|
artikel
|
| 165 |
The impact of a gamified versus traditional curriculum on resident education in metabolic dysfunction-associated steatotic liver disease management
|
Jnani, Jack
|
|
|
19 |
3S |
p. e101-e102
|
artikel
|
| 166 |
The impact of genetic testing on physician practice in specialized cardiovascular clinics
|
Hamid, Arsalan
|
|
|
19 |
3S |
p. e73-e74
|
artikel
|
| 167 |
The lipid leaderboards: A virtual gamified curriculum to educate internal medicine residents on guideline-based management of hyperlipidemia
|
Hsieh, Ji-Cheng Jason
|
|
|
19 |
3S |
p. e2
|
artikel
|
| 168 |
The PCSK9 paradox: Evolocumab-induced rise in low-density lipoprotein cholesterol in an adult with metastatic uterine cancer on pembrolizumab
|
Sheth, Sohum
|
|
|
19 |
3S |
p. e30
|
artikel
|
| 169 |
*The promise of progress in cardiovascular residual risk reduction: A complex case of lipoprotein management in pregnancy
|
Safarova, Maya
|
|
|
19 |
3S |
p. e82-e83
|
artikel
|
| 170 |
Transforming care in familial chylomicronemia syndrome: Virtual CME enhances physician expertise and confidence
|
Harris, Margaret
|
|
|
19 |
3S |
p. e106
|
artikel
|
| 171 |
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report
|
Fares, Hadeel Al
|
|
|
19 |
3S |
p. e84
|
artikel
|
| 172 |
Trends and experience with lipoprotein(a) testing in a large academic medical center
|
Zirille, Francis
|
|
|
19 |
3S |
p. e63-e64
|
artikel
|
| 173 |
Triple hit: Familial hypercholesterolemia, elevated Lp(a), and apoB defect driving early aortic stenosis in a 56-year-old female
|
Patel, Nidhi
|
|
|
19 |
3S |
p. e78-e79
|
artikel
|
| 174 |
Two young sisters with sitosterolemia due to a homozygous mutation in ABCG5: Phenotypic heterogeneity and effect of ezetimibe on lipids and appetite
|
Brown, Emily
|
|
|
19 |
3S |
p. e79
|
artikel
|
| 175 |
*Universal lipoprotein(a) screening of youth and reverse cascade screening at a primary care clinic
|
Hyman, Joshua
|
|
|
19 |
3S |
p. e117-e118
|
artikel
|
| 176 |
Use of statin therapy in the achievement of LDL targets for the secondary prevention of atherosclerotic cardiovascular disease
|
Scerbo, Danielle
|
|
|
19 |
3S |
p. e92
|
artikel
|
| 177 |
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions
|
Rege, Rahul
|
|
|
19 |
3S |
p. e11-e12
|
artikel
|
| 178 |
Variations in statin prescribing patterns and LDL goal attainment for secondary prevention of atherosclerotic cardiovascular disease by sex
|
Gopinath, Meera
|
|
|
19 |
3S |
p. e46-e47
|
artikel
|
| 179 |
Variations statin prescribing pattern and LDL goal attainment for secondary prevention of atherosclerotic cardiovascular disease by language and race
|
Santiago, Hector
|
|
|
19 |
3S |
p. e47
|
artikel
|
| 180 |
† VERVE-102, a clinical stage in vivo base editing medicine, leads to potent and precise inactivation of PCSK9 in preclinical studies
|
Flight, Patrick
|
|
|
19 |
3S |
p. e68
|
artikel
|
Tijdschrift beschrijving